Precision LBx Summit

Precision LBx Summit is organized by Hanson Wade and would be held during Jan 30 - Feb 1, 2017 at Marriott Marquis San Diego Marina, San Diego, California, United States of America.

Touted as the holy grail of diagnostics, liquid biopsy promises real time longitudinal patient monitoring and cost effective diagnostic screening. However, still in its infancy, the field is grappling with proving and advancing the clinical utility of liquid biopsies.

Coinciding with the first FDA approval of a clinical liquid biopsy test, the inaugural Precision LBx Summit will help large biopharma, research laboratories and diagnostic organizations capitalize on this potential. Bringing together leaders from academia, biopharma and Dx developers to build the cross-industry collaborative platform that will dictate the direction and rhetoric of the evolving liquid biopsy story.

Blood-based liquid biopsies have laid the roadmap thus far through validated biomarker discoveries, such as CTCs and ctDNA, and emerging biomarkers, such as exosomes and miRNA. Further growth in the field continues through non blood-based liquid biopsies, such as spinal fluid and urine, proving that the market potential of liquid biopsies is vast and far-reaching outside of oncology.

Precision LBx Summit is dedicated to showcasing the tangible clinical applications of LBx and realizing the big picture scope in the potential of fluid based biomarker diagnostics.

Top 5 Reasons to Attend Precision LBx Summit :
• Analyze the cutting edge applications of liquid biopsies and how to prove their clinical utility with case studies from Astrazeneca, Genentech, Mayo Clinic and Merck
• Understand the arsenal of biomarkers and biofluids and evaluate their potential as non-invasive diagnostics with insight from Novartis and Eisai
• Challenge and debate how we overcome the lack of standardization and validation within the field alongside Pfizer, TGen and Bayer
• Hear from Pfizer and UCSD as they share their secrets for advancing diagnostic technology to provide better, analysis and interpretation of biomarker data
• Join the likes of MD Anderson and Johns Hopkins to define the roadmap for furthering the future impact of liquid biopsies in the evolving precision medicine paradigm

Attend this summit to :
• Understand the limitations and potential of a multitude of biomarkers and biofluids for use as clinical indicators
• Define your roadmap for successfully developing and implementing clinically useful liquid biopsy diagnostics
• Join an exclusive community of industry experts championing the utilization of non-invasive diagnostics

Prices :
Conference Only (Industry ) : USD 2699
Conference + 1 Workshop (Industry) : USD 3198
Workshop Only (Industry): USD 699

Speakers :
Stefan Scherer (Vice President, Global Head Correlative Science, Novartis), Pallavi Sachdev (Associate Director, Oncology Biomarker Research, Clinical Development, Eisai), Kenneth Thress (Director, Oncology Translational Science, Astrazeneca), Thomas Schlange (Senior Biomarker Scientist, Bayer and EFPIA Coordinator, IMI Cancer-ID), Jean-Francois Martini (Senior Director, Translational Oncology, EDTO group, Pfizer), George Vasmatzis (Co-Director Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic), Samir Hanash (Director, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center)